CBD has been a big conversation related to underwriting, and a federal comment period is open.
The Food and Drug Administration is accepting comments now about the marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds.
Long discouraged as possible underwriters, businesses related to marijuana and cannabis-derived products have gained mainstream acceptance in several states. The FDA has yet to rule on these matters, which could influence the FCC’s decisions related to underwriting and CBD.
For those interested, comments must be submitted via the electronic filing system by 11:59 p.m. Eastern Time at the end of July 16, 2019.
